Global Immune Checkpoint Inhibitors Market By Drug Class (CTLA-4 Inhibitors, LAG-3 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors); By Cancer Type (Bladder Cancer, Breast Cancer, Lung Cancer, Head and neck cancers, Hodgkin lymphoma, Kidney Cancer, Melanoma, Non-small cell lung cancer, Stomach cancer, Colorectal cancer); By End Users (Hospitals and Clinics, Specialty Clinics, Research Organizations); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
Immune checkpoint inhibitors (ICIs) happen to be a type of cancer immunotherapy drug that aids the immune system recognize and attack cancer cells. The immune system possesses multiple checkpoints or regulatory mechanisms in place to prevent it from attacking healthy cells. Cancer cells sometimes are likely to use these checkpoints to avoid being recognized and attacked by the immune system. These inhibitors function by blocking these checkpoints, thus allowing the immune system to recognize and attack cancer cells. The most commonly targeted checkpoint is the programmed cell death protein 1 (PD-1) receptor and its ligand PD-L1. When these two molecules interact, they stop T cells from attacking cancer cells. By blocking this interaction, the immune checkpoint inhibitors can allow T cells to attack cancer cells. The global immune checkpoint inhibitors market has been growing aggressively as it has been approved for the treatment of various types of cancer, including melanoma, lung cancer, bladder cancer, kidney cancer, head and neck cancer, and others. It's important to note that while ICIs have shown remarkable success in some patients, they may not work for everyone and can also cause side effects. Hence, it's crucial to work closely with a healthcare provider to determine if ICIs are an appropriate treatment option and to monitor for any potential side effects.
In terms of revenue, the global immune checkpoint inhibitors market was valued at US$ 36,786.44 Mn in 2022, growing at a CAGR of 16.9% over the forecast period (2023 – 2031). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Cancer Type Outlook
Based on the cancer type outlook, the global immune checkpoint inhibitors market has been segregated into bladder cancer, breast cancer, lung cancer, head and neck cancers, hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, stomach cancer, and colorectal cancer. Rising number of smokers along with increasing pollution cross the globe is the reason why the number of lung cancer cases are going upwards. Hence the lung cancer segment accounts for most of the revenue made by this market.
Region Outlook
On the basis of the region, the continent of North America has been minting maximum money for the global immune checkpoint inhibitors market in the year 2022. Despite the hub of massive development, the region is also seeing surge in the pollution levels and increasing population living unhealthy lifestyle. Though, the advanced healthcare infrastructure proves helpful for the people and ultimately for this market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global immune checkpoint inhibitors market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global immune checkpoint inhibitors market are:
- AstraZeneca
- BeiGene, Inc.
- Bristol Myers Squibb
- DeuterOncology
- Eli Lilly and Company
- F. Hoffman-La Roche Ltd
- GSK plc
- Merck & Co. Inc
- Novartis AG
- Palleon Pharmaceuticals
- Sanofi
- Other Market Participants
Global Immune Checkpoint Inhibitors Market:
By Drug Class
- CTLA-4 inhibitors
- LAG-3 inhibitors
- PD-1 inhibitors
- PD-L1 inhibitors
By Cancer Type
- Bladder Cancer
- Breast Cancer
- Lung Cancer
- Head and neck cancers
- Hodgkin lymphoma
- Kidney cancer
- Melanoma
- Non-small cell lung cancer
- Stomach cancer
- Colorectal cancer
- Others
By End Users
- Hospitals and clinics
- Specialty Clinics
- Research Organizations
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2022
1.2.3. Forecast
Years: 2023 – 2031
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Immune Checkpoint Inhibitors Market
6. Market Synopsis:
Immune Checkpoint Inhibitors Market
7. Immune Checkpoint Inhibitors Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Immune Checkpoint Inhibitors Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Immune Checkpoint Inhibitors Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Immune Checkpoint Inhibitors Market
8. Global Immune Checkpoint Inhibitors Market Analysis and
Forecasts, 2023 – 2031
8.1. Overview
8.1.1. Global
Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
8.2. Global
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Drug
Class
8.2.1. CTLA-4
inhibitors
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2022
8.2.1.3. Market Forecast, 2023 – 2031
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 - 2022
8.2.1.5.1.2. Market
Forecast, 2023 – 2031
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2022
8.2.1.5.2.2. Market
Forecast, 2023 – 2031
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2022
8.2.1.5.3.2. Market
Forecast, 2023 – 2031
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2022
8.2.1.5.4.2. Market
Forecast, 2023 – 2031
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 - 2022
8.2.1.5.5.2. Market
Forecast, 2023 – 2031
8.2.2. LAG-3
inhibitors
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2022
8.2.2.3. Market Forecast, 2023 – 2031
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 - 2022
8.2.2.5.1.2. Market
Forecast, 2023 – 2031
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2022
8.2.2.5.2.2. Market
Forecast, 2023 – 2031
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2022
8.2.2.5.3.2. Market
Forecast, 2023 – 2031
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2022
8.2.2.5.4.2. Market
Forecast, 2023 – 2031
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 - 2022
8.2.2.5.5.2. Market
Forecast, 2023 – 2031
8.2.3. PD-1
inhibitors
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2022
8.2.3.3. Market Forecast, 2023 – 2031
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 - 2022
8.2.3.5.1.2. Market
Forecast, 2023 – 2031
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2022
8.2.3.5.2.2. Market
Forecast, 2023 – 2031
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2022
8.2.3.5.3.2. Market
Forecast, 2023 – 2031
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2022
8.2.3.5.4.2. Market
Forecast, 2023 – 2031
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 - 2022
8.2.3.5.5.2. Market
Forecast, 2023 – 2031
8.2.4. PD-L1
inhibitors
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2022
8.2.4.3. Market Forecast, 2023 – 2031
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 - 2022
8.2.4.5.1.2. Market
Forecast, 2023 – 2031
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2022
8.2.4.5.2.2. Market
Forecast, 2023 – 2031
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2022
8.2.4.5.3.2. Market
Forecast, 2023 – 2031
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2022
8.2.4.5.4.2. Market
Forecast, 2023 – 2031
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 - 2022
8.2.4.5.5.2. Market
Forecast, 2023 – 2031
8.3. Key
Segment for Channeling Investments
8.3.1. By Drug
Class
9. Global Immune Checkpoint Inhibitors Market Analysis and
Forecasts, 2023 – 2031
9.1. Overview
9.2. Global
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Cancer Type
9.2.1. Bladder
Cancer
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2022
9.2.1.3. Market Forecast, 2023 – 2031
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 - 2022
9.2.1.5.1.2. Market
Forecast, 2023 – 2031
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2022
9.2.1.5.2.2. Market
Forecast, 2023 – 2031
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2022
9.2.1.5.3.2. Market
Forecast, 2023 – 2031
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2022
9.2.1.5.4.2. Market
Forecast, 2023 – 2031
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 - 2022
9.2.1.5.5.2. Market
Forecast, 2023 – 2031
9.2.2. Breast
Cancer
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2022
9.2.2.3. Market Forecast, 2023 – 2031
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 - 2022
9.2.2.5.1.2. Market
Forecast, 2023 – 2031
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2022
9.2.2.5.2.2. Market
Forecast, 2023 – 2031
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2022
9.2.2.5.3.2. Market
Forecast, 2023 – 2031
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2022
9.2.2.5.4.2. Market
Forecast, 2023 – 2031
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 - 2022
9.2.2.5.5.2. Market
Forecast, 2023 – 2031
9.2.3. Lung
Cancer
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2022
9.2.3.3. Market Forecast, 2023 – 2031
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 - 2022
9.2.3.5.1.2. Market
Forecast, 2023 – 2031
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2022
9.2.3.5.2.2. Market
Forecast, 2023 – 2031
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2022
9.2.3.5.3.2. Market
Forecast, 2023 – 2031
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2022
9.2.3.5.4.2. Market
Forecast, 2023 – 2031
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 - 2022
9.2.3.5.5.2. Market
Forecast, 2023 – 2031
9.2.4. Head and
Neck Cancers
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2022
9.2.4.3. Market Forecast, 2023 – 2031
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 - 2022
9.2.4.5.1.2. Market
Forecast, 2023 – 2031
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2022
9.2.4.5.2.2. Market
Forecast, 2023 – 2031
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2022
9.2.4.5.3.2. Market
Forecast, 2023 – 2031
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2022
9.2.4.5.4.2. Market
Forecast, 2023 – 2031
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 - 2022
9.2.4.5.5.2. Market
Forecast, 2023 – 2031
9.2.5. Hodgkin
lymphoma
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2022
9.2.5.3. Market Forecast, 2023 – 2031
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 - 2022
9.2.5.5.1.2. Market
Forecast, 2023 – 2031
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2022
9.2.5.5.2.2. Market
Forecast, 2023 – 2031
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2022
9.2.5.5.3.2. Market
Forecast, 2023 – 2031
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2022
9.2.5.5.4.2. Market
Forecast, 2023 – 2031
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 - 2022
9.2.5.5.5.2. Market
Forecast, 2023 – 2031
9.2.6. Kidney
Cancer
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2022
9.2.6.3. Market Forecast, 2023 – 2031
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 - 2022
9.2.6.5.1.2. Market
Forecast, 2023 – 2031
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2022
9.2.6.5.2.2. Market
Forecast, 2023 – 2031
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2022
9.2.6.5.3.2. Market
Forecast, 2023 – 2031
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2022
9.2.6.5.4.2. Market
Forecast, 2023 – 2031
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 - 2022
9.2.6.5.5.2. Market
Forecast, 2023 – 2031
9.2.7. Melanoma
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2022
9.2.7.3. Market Forecast, 2023 – 2031
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2015 - 2022
9.2.7.5.1.2. Market
Forecast, 2023 – 2031
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2022
9.2.7.5.2.2. Market
Forecast, 2023 – 2031
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2022
9.2.7.5.3.2. Market
Forecast, 2023 – 2031
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2022
9.2.7.5.4.2. Market
Forecast, 2023 – 2031
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2015 - 2022
9.2.7.5.5.2. Market
Forecast, 2023 – 2031
9.2.8. Non-small
cell lung cancer
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2022
9.2.8.3. Market Forecast, 2023 – 2031
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North
America
9.2.8.5.1.1. Market
Estimation, 2015 - 2022
9.2.8.5.1.2. Market
Forecast, 2023 – 2031
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2022
9.2.8.5.2.2. Market
Forecast, 2023 – 2031
9.2.8.5.3. Asia
Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2022
9.2.8.5.3.2. Market
Forecast, 2023 – 2031
9.2.8.5.4. Middle
East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2022
9.2.8.5.4.2. Market
Forecast, 2023 – 2031
9.2.8.5.5. Latin
America
9.2.8.5.5.1. Market
Estimation, 2015 - 2022
9.2.8.5.5.2. Market
Forecast, 2023 – 2031
9.2.9. Stomach
cancer
9.2.9.1. Definition
9.2.9.2. Market Estimation and Penetration, 2015 - 2022
9.2.9.3. Market Forecast, 2023 – 2031
9.2.9.4. Compound Annual Growth Rate (CAGR)
9.2.9.5. Regional Bifurcation
9.2.9.5.1. North
America
9.2.9.5.1.1. Market
Estimation, 2015 - 2022
9.2.9.5.1.2. Market
Forecast, 2023 – 2031
9.2.9.5.2. Europe
9.2.9.5.2.1. Market
Estimation, 2015 - 2022
9.2.9.5.2.2. Market
Forecast, 2023 – 2031
9.2.9.5.3. Asia
Pacific
9.2.9.5.3.1. Market
Estimation, 2015 - 2022
9.2.9.5.3.2. Market
Forecast, 2023 – 2031
9.2.9.5.4. Middle
East and Africa
9.2.9.5.4.1. Market
Estimation, 2015 - 2022
9.2.9.5.4.2. Market
Forecast, 2023 – 2031
9.2.9.5.5. Latin
America
9.2.9.5.5.1. Market
Estimation, 2015 - 2022
9.2.9.5.5.2. Market
Forecast, 2023 – 2031
9.2.10. Colorectal
cancer
9.2.10.1. Definition
9.2.10.2. Market Estimation and Penetration, 2015 - 2022
9.2.10.3. Market Forecast, 2023 – 2031
9.2.10.4. Compound Annual Growth Rate (CAGR)
9.2.10.5. Regional Bifurcation
9.2.10.5.1. North
America
9.2.10.5.1.1. Market
Estimation, 2015 - 2022
9.2.10.5.1.2. Market
Forecast, 2023 – 2031
9.2.10.5.2. Europe
9.2.10.5.2.1. Market
Estimation, 2015 - 2022
9.2.10.5.2.2. Market
Forecast, 2023 – 2031
9.2.10.5.3. Asia
Pacific
9.2.10.5.3.1. Market
Estimation, 2015 - 2022
9.2.10.5.3.2. Market
Forecast, 2023 – 2031
9.2.10.5.4. Middle
East and Africa
9.2.10.5.4.1. Market
Estimation, 2015 - 2022
9.2.10.5.4.2. Market
Forecast, 2023 – 2031
9.2.10.5.5. Latin
America
9.2.10.5.5.1. Market
Estimation, 2015 - 2022
9.2.10.5.5.2. Market
Forecast, 2023 – 2031
9.2.11. Others
9.2.11.1. Definition
9.2.11.2. Market Estimation and Penetration, 2015 - 2022
9.2.11.3. Market Forecast, 2023 – 2031
9.2.11.4. Compound Annual Growth Rate (CAGR)
9.2.11.5. Regional Bifurcation
9.2.11.5.1. North
America
9.2.11.5.1.1. Market
Estimation, 2015 - 2022
9.2.11.5.1.2. Market
Forecast, 2023 – 2031
9.2.11.5.2. Europe
9.2.11.5.2.1. Market
Estimation, 2015 - 2022
9.2.11.5.2.2. Market
Forecast, 2023 – 2031
9.2.11.5.3. Asia
Pacific
9.2.11.5.3.1. Market
Estimation, 2015 - 2022
9.2.11.5.3.2. Market
Forecast, 2023 – 2031
9.2.11.5.4. Middle
East and Africa
9.2.11.5.4.1. Market
Estimation, 2015 - 2022
9.2.11.5.4.2. Market
Forecast, 2023 – 2031
9.2.11.5.5. Latin
America
9.2.11.5.5.1. Market
Estimation, 2015 - 2022
9.2.11.5.5.2. Market
Forecast, 2023 – 2031
9.3. Key
Segment for Channeling Investments
9.3.1. By
Cancer Type
10. Global Immune Checkpoint Inhibitors Market Analysis and
Forecasts, 2023 – 2031
10.1. Overview
10.2. Global
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By End
Users
10.2.1. Hospitals
and clinics
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2022
10.2.1.3. Market Forecast, 2023 – 2031
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 - 2022
10.2.1.5.1.2. Market
Forecast, 2023 – 2031
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2022
10.2.1.5.2.2. Market
Forecast, 2023 – 2031
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2022
10.2.1.5.3.2. Market
Forecast, 2023 – 2031
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2022
10.2.1.5.4.2. Market
Forecast, 2023 – 2031
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 - 2022
10.2.1.5.5.2. Market
Forecast, 2023 – 2031
10.2.2. Specialty
Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2022
10.2.2.3. Market Forecast, 2023 – 2031
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 - 2022
10.2.2.5.1.2. Market
Forecast, 2023 – 2031
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2022
10.2.2.5.2.2. Market
Forecast, 2023 – 2031
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2022
10.2.2.5.3.2. Market
Forecast, 2023 – 2031
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2022
10.2.2.5.4.2. Market
Forecast, 2023 – 2031
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 - 2022
10.2.2.5.5.2. Market
Forecast, 2023 – 2031
10.2.3. Research
Organizations
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2022
10.2.3.3. Market Forecast, 2023 – 2031
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 - 2022
10.2.3.5.1.2. Market
Forecast, 2023 – 2031
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2022
10.2.3.5.2.2. Market
Forecast, 2023 – 2031
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2022
10.2.3.5.3.2. Market
Forecast, 2023 – 2031
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2022
10.2.3.5.4.2. Market
Forecast, 2023 – 2031
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 - 2022
10.2.3.5.5.2. Market
Forecast, 2023 – 2031
10.3. Key
Segment for Channeling Investments
10.3.1. By End
Users
11. North America Immune Checkpoint Inhibitors Market Analysis
and Forecasts, 2023 – 2031
11.1. Overview
11.1.1. North
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
11.2. North
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Drug Class
11.2.1. CTLA-4
inhibitors
11.2.2. LAG-3
inhibitors
11.2.3. PD-1
inhibitors
11.2.4. PD-L1
inhibitors
11.3. North
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Cancer Type
11.3.1. Bladder
Cancer
11.3.2. Breast
Cancer
11.3.3. Lung
Cancer
11.3.4. Head
and Neck Cancers
11.3.5. Hodgkin
lymphoma
11.3.6. Kidney
Cancer
11.3.7. Melanoma
11.3.8. Non-small
cell lung cancer
11.3.9. Stomach
cancer
11.3.10. Colorectal
cancer
11.3.11. Others
11.4. North
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
End Users
11.4.1. Hospitals
and clinics
11.4.2. Specialty
Clinics
11.4.3. Research
Organizations
11.5. North
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
11.5.1.1.1. CTLA-4
inhibitors
11.5.1.1.2. LAG-3
inhibitors
11.5.1.1.3. PD-1
inhibitors
11.5.1.1.4. PD-L1
inhibitors
11.5.1.2. U.S Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
11.5.1.2.1. Bladder
Cancer
11.5.1.2.2. Breast
Cancer
11.5.1.2.3. Lung
Cancer
11.5.1.2.4. Head
and Neck Cancers
11.5.1.2.5. Hodgkin
lymphoma
11.5.1.2.6. Kidney
Cancer
11.5.1.2.7. Melanoma
11.5.1.2.8. Non-small
cell lung cancer
11.5.1.2.9. Stomach
cancer
11.5.1.2.10. Colorectal
cancer
11.5.1.2.11. Others
11.5.1.3. U.S Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
11.5.1.3.1. Hospitals
and clinics
11.5.1.3.2. Specialty
Clinics
11.5.1.3.3. Research
Organizations
11.5.2. Canada
11.5.2.1. Canada Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
11.5.2.1.1. CTLA-4
inhibitors
11.5.2.1.2. LAG-3
inhibitors
11.5.2.1.3. PD-1
inhibitors
11.5.2.1.4. PD-L1
inhibitors
11.5.2.2. Canada Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
11.5.2.2.1. Bladder
Cancer
11.5.2.2.2. Breast
Cancer
11.5.2.2.3. Lung
Cancer
11.5.2.2.4. Head
and Neck Cancers
11.5.2.2.5. Hodgkin
lymphoma
11.5.2.2.6. Kidney
Cancer
11.5.2.2.7. Melanoma
11.5.2.2.8. Non-small
cell lung cancer
11.5.2.2.9. Stomach
cancer
11.5.2.2.10. Colorectal
cancer
11.5.2.2.11. Others
11.5.2.3. Canada Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
11.5.2.3.1. Hospitals
and clinics
11.5.2.3.2. Specialty
Clinics
11.5.2.3.3. Research
Organizations
11.5.3. Mexico
11.5.3.1. Mexico Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
11.5.3.1.1. CTLA-4
inhibitors
11.5.3.1.2. LAG-3
inhibitors
11.5.3.1.3. PD-1
inhibitors
11.5.3.1.4. PD-L1
inhibitors
11.5.3.2. Mexico Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
11.5.3.2.1. Bladder
Cancer
11.5.3.2.2. Breast
Cancer
11.5.3.2.3. Lung
Cancer
11.5.3.2.4. Head
and Neck Cancers
11.5.3.2.5. Hodgkin
lymphoma
11.5.3.2.6. Kidney
Cancer
11.5.3.2.7. Melanoma
11.5.3.2.8. Non-small
cell lung cancer
11.5.3.2.9. Stomach
cancer
11.5.3.2.10. Colorectal
cancer
11.5.3.2.11. Others
11.5.3.3. Mexico Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
11.5.3.3.1. Hospitals
and clinics
11.5.3.3.2. Specialty
Clinics
11.5.3.3.3. Research
Organizations
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Drug Class
11.5.4.1.1. CTLA-4
inhibitors
11.5.4.1.2. LAG-3
inhibitors
11.5.4.1.3. PD-1
inhibitors
11.5.4.1.4. PD-L1
inhibitors
11.5.4.2. Rest of North America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
11.5.4.2.1. Bladder
Cancer
11.5.4.2.2. Breast
Cancer
11.5.4.2.3. Lung
Cancer
11.5.4.2.4. Head
and Neck Cancers
11.5.4.2.5. Hodgkin
lymphoma
11.5.4.2.6. Kidney
Cancer
11.5.4.2.7. Melanoma
11.5.4.2.8. Non-small
cell lung cancer
11.5.4.2.9. Stomach
cancer
11.5.4.2.10. Colorectal
cancer
11.5.4.2.11. Others
11.5.4.3. Rest of North America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.4.3.1. Hospitals
and clinics
11.5.4.3.2. Specialty
Clinics
11.5.4.3.3. Research
Organizations
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Drug
Class
11.6.3. By
Cancer Type
11.6.4. By End
Users
12. Europe Immune Checkpoint Inhibitors Market Analysis and
Forecasts, 2023 – 2031
12.1. Overview
12.1.1. Europe
Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
12.2. Europe
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Drug
Class
12.2.1. CTLA-4 inhibitors
12.2.2. LAG-3
inhibitors
12.2.3. PD-1
inhibitors
12.2.4. PD-L1
inhibitors
12.3. Europe
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Cancer
Type
12.3.1. Bladder
Cancer
12.3.2. Breast
Cancer
12.3.3. Lung
Cancer
12.3.4. Head
and Neck Cancers
12.3.5. Hodgkin
lymphoma
12.3.6. Kidney
Cancer
12.3.7. Melanoma
12.3.8. Non-small
cell lung cancer
12.3.9. Stomach
cancer
12.3.10. Colorectal
cancer
12.3.11. Others
12.4. Europe
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By End
Users
12.4.1. Hospitals
and clinics
12.4.2. Specialty
Clinics
12.4.3. Research
Organizations
12.5. Europe
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
12.5.1.1.1. CTLA-4
inhibitors
12.5.1.1.2. LAG-3
inhibitors
12.5.1.1.3. PD-1
inhibitors
12.5.1.1.4. PD-L1
inhibitors
12.5.1.2. France Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
12.5.1.2.1. Bladder
Cancer
12.5.1.2.2. Breast
Cancer
12.5.1.2.3. Lung
Cancer
12.5.1.2.4. Head
and Neck Cancers
12.5.1.2.5. Hodgkin
lymphoma
12.5.1.2.6. Kidney
Cancer
12.5.1.2.7. Melanoma
12.5.1.2.8. Non-small
cell lung cancer
12.5.1.2.9. Stomach
cancer
12.5.1.2.10. Colorectal
cancer
12.5.1.2.11. Others
12.5.1.3. France Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
12.5.1.3.1. Hospitals
and clinics
12.5.1.3.2. Specialty
Clinics
12.5.1.3.3. Research
Organizations
12.5.2. The UK
12.5.2.1. The UK Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
12.5.2.1.1. CTLA-4
inhibitors
12.5.2.1.2. LAG-3
inhibitors
12.5.2.1.3. PD-1
inhibitors
12.5.2.1.4. PD-L1
inhibitors
12.5.2.2. The UK Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
12.5.2.2.1. Bladder
Cancer
12.5.2.2.2. Breast
Cancer
12.5.2.2.3. Lung
Cancer
12.5.2.2.4. Head
and Neck Cancers
12.5.2.2.5. Hodgkin
lymphoma
12.5.2.2.6. Kidney
Cancer
12.5.2.2.7. Melanoma
12.5.2.2.8. Non-small
cell lung cancer
12.5.2.2.9. Stomach
cancer
12.5.2.2.10. Colorectal
cancer
12.5.2.2.11. Others
12.5.2.3. The UK Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
12.5.2.3.1. Hospitals
and clinics
12.5.2.3.2. Specialty
Clinics
12.5.2.3.3. Research
Organizations
12.5.3. Spain
12.5.3.1. Spain Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
12.5.3.1.1. CTLA-4
inhibitors
12.5.3.1.2. LAG-3
inhibitors
12.5.3.1.3. PD-1
inhibitors
12.5.3.1.4. PD-L1
inhibitors
12.5.3.2. Spain Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.3.2.1. Bladder
Cancer
12.5.3.2.2. Breast
Cancer
12.5.3.2.3. Lung
Cancer
12.5.3.2.4. Head
and Neck Cancers
12.5.3.2.5. Hodgkin
lymphoma
12.5.3.2.6. Kidney
Cancer
12.5.3.2.7. Melanoma
12.5.3.2.8. Non-small
cell lung cancer
12.5.3.2.9. Stomach
cancer
12.5.3.2.10. Colorectal
cancer
12.5.3.2.11. Others
12.5.3.3. Spain Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.3.3.1. Hospitals
and clinics
12.5.3.3.2. Specialty
Clinics
12.5.3.3.3. Research
Organizations
12.5.4. Germany
12.5.4.1. Germany Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
12.5.4.1.1. CTLA-4
inhibitors
12.5.4.1.2. LAG-3
inhibitors
12.5.4.1.3. PD-1
inhibitors
12.5.4.1.4. PD-L1
inhibitors
12.5.4.2. Germany Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
12.5.4.2.1. Bladder
Cancer
12.5.4.2.2. Breast
Cancer
12.5.4.2.3. Lung
Cancer
12.5.4.2.4. Head
and Neck Cancers
12.5.4.2.5. Hodgkin
lymphoma
12.5.4.2.6. Kidney
Cancer
12.5.4.2.7. Melanoma
12.5.4.2.8. Non-small
cell lung cancer
12.5.4.2.9. Stomach
cancer
12.5.4.2.10. Colorectal
cancer
12.5.4.2.11. Others
12.5.4.3. Germany Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
12.5.4.3.1. Hospitals
and clinics
12.5.4.3.2. Specialty
Clinics
12.5.4.3.3. Research
Organizations
12.5.5. Italy
12.5.5.1. Italy Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
12.5.5.1.1. CTLA-4
inhibitors
12.5.5.1.2. LAG-3
inhibitors
12.5.5.1.3. PD-1
inhibitors
12.5.5.1.4. PD-L1
inhibitors
12.5.5.2. Italy Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
12.5.5.2.1. Bladder
Cancer
12.5.5.2.2. Breast
Cancer
12.5.5.2.3. Lung
Cancer
12.5.5.2.4. Head
and Neck Cancers
12.5.5.2.5. Hodgkin
lymphoma
12.5.5.2.6. Kidney
Cancer
12.5.5.2.7. Melanoma
12.5.5.2.8. Non-small
cell lung cancer
12.5.5.2.9. Stomach
cancer
12.5.5.2.10. Colorectal
cancer
12.5.5.2.11. Others
12.5.5.3. Italy Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
12.5.5.3.1. Hospitals
and clinics
12.5.5.3.2. Specialty
Clinics
12.5.5.3.3. Research
Organizations
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Drug Class
12.5.6.1.1. CTLA-4
inhibitors
12.5.6.1.2. LAG-3
inhibitors
12.5.6.1.3. PD-1
inhibitors
12.5.6.1.4. PD-L1
inhibitors
12.5.6.2. Nordic Countries Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
12.5.6.2.1. Bladder
Cancer
12.5.6.2.2. Breast
Cancer
12.5.6.2.3. Lung
Cancer
12.5.6.2.4. Head
and Neck Cancers
12.5.6.2.5. Hodgkin
lymphoma
12.5.6.2.6. Kidney
Cancer
12.5.6.2.7. Melanoma
12.5.6.2.8. Non-small
cell lung cancer
12.5.6.2.9. Stomach
cancer
12.5.6.2.10. Colorectal
cancer
12.5.6.2.11. Others
12.5.6.3. Nordic Countries Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By End Users
12.5.6.3.1. Hospitals
and clinics
12.5.6.3.2. Specialty
Clinics
12.5.6.3.3. Research
Organizations
12.5.6.4. Nordic Countries Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
12.5.7.1.1. CTLA-4
inhibitors
12.5.7.1.2. LAG-3
inhibitors
12.5.7.1.3. PD-1
inhibitors
12.5.7.1.4. PD-L1
inhibitors
12.5.7.2. Benelux Union Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Cancer Type
12.5.7.2.1. Bladder
Cancer
12.5.7.2.2. Breast
Cancer
12.5.7.2.3. Lung
Cancer
12.5.7.2.4. Head
and Neck Cancers
12.5.7.2.5. Hodgkin
lymphoma
12.5.7.2.6. Kidney
Cancer
12.5.7.2.7. Melanoma
12.5.7.2.8. Non-small
cell lung cancer
12.5.7.2.9. Stomach
cancer
12.5.7.2.10. Colorectal
cancer
12.5.7.2.11. Others
12.5.7.3. Benelux Union Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By End Users
12.5.7.3.1. Hospitals
and clinics
12.5.7.3.2. Specialty
Clinics
12.5.7.3.3. Research
Organizations
12.5.7.4. Benelux Union Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Drug Class
12.5.8.1.1. CTLA-4
inhibitors
12.5.8.1.2. LAG-3
inhibitors
12.5.8.1.3. PD-1
inhibitors
12.5.8.1.4. PD-L1
inhibitors
12.5.8.2. Rest of Europe Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
12.5.8.2.1. Bladder
Cancer
12.5.8.2.2. Breast
Cancer
12.5.8.2.3. Lung
Cancer
12.5.8.2.4. Head
and Neck Cancers
12.5.8.2.5. Hodgkin
lymphoma
12.5.8.2.6. Kidney
Cancer
12.5.8.2.7. Melanoma
12.5.8.2.8. Non-small
cell lung cancer
12.5.8.2.9. Stomach
cancer
12.5.8.2.10. Colorectal
cancer
12.5.8.2.11. Others
12.5.8.3. Rest of Europe Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By End Users
12.5.8.3.1. Hospitals
and clinics
12.5.8.3.2. Specialty
Clinics
12.5.8.3.3. Research
Organizations
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Drug
Class
12.6.3. By
Cancer Type
12.6.4. By End
Users
13. Asia Pacific Immune Checkpoint Inhibitors Market Analysis and
Forecasts, 2023 – 2031
13.1. Overview
13.1.1. Asia
Pacific Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
13.2. Asia
Pacific Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Drug Class
13.2.1. CTLA-4
inhibitors
13.2.2. LAG-3
inhibitors
13.2.3. PD-1
inhibitors
13.2.4. PD-L1
inhibitors
13.3. Asia
Pacific Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Cancer
Type
13.3.1. Bladder
Cancer
13.3.2. Breast
Cancer
13.3.3. Lung
Cancer
13.3.4. Head
and Neck Cancers
13.3.5. Hodgkin
lymphoma
13.3.6. Kidney
Cancer
13.3.7. Melanoma
13.3.8. Non-small
cell lung cancer
13.3.9. Stomach
cancer
13.3.10. Colorectal
cancer
13.3.11. Others
13.4. Asia
Pacific Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
End Users
13.4.1. Hospitals
and clinics
13.4.2. Specialty
Clinics
13.4.3. Research
Organizations
13.5. Asia
Pacific Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
13.5.1.1.1. CTLA-4
inhibitors
13.5.1.1.2. LAG-3
inhibitors
13.5.1.1.3. PD-1
inhibitors
13.5.1.1.4. PD-L1
inhibitors
13.5.1.2. China Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.1.2.1. Bladder
Cancer
13.5.1.2.2. Breast
Cancer
13.5.1.2.3. Lung
Cancer
13.5.1.2.4. Head
and Neck Cancers
13.5.1.2.5. Hodgkin
lymphoma
13.5.1.2.6. Kidney
Cancer
13.5.1.2.7. Melanoma
13.5.1.2.8. Non-small
cell lung cancer
13.5.1.2.9. Stomach
cancer
13.5.1.2.10. Colorectal
cancer
13.5.1.2.11. Others
13.5.1.3. China Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.1.3.1. Hospitals
and clinics
13.5.1.3.2. Specialty
Clinics
13.5.1.3.3. Research
Organizations
13.5.2. Japan
13.5.2.1. Japan Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
13.5.2.1.1. CTLA-4
inhibitors
13.5.2.1.2. LAG-3
inhibitors
13.5.2.1.3. PD-1
inhibitors
13.5.2.1.4. PD-L1
inhibitors
13.5.2.2. Japan Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.2.2.1. Bladder
Cancer
13.5.2.2.2. Breast
Cancer
13.5.2.2.3. Lung
Cancer
13.5.2.2.4. Head
and Neck Cancers
13.5.2.2.5. Hodgkin
lymphoma
13.5.2.2.6. Kidney
Cancer
13.5.2.2.7. Melanoma
13.5.2.2.8. Non-small
cell lung cancer
13.5.2.2.9. Stomach
cancer
13.5.2.2.10. Colorectal
cancer
13.5.2.2.11. Others
13.5.2.3. Japan Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.2.3.1. Hospitals
and clinics
13.5.2.3.2. Specialty
Clinics
13.5.2.3.3. Research
Organizations
13.5.3. India
13.5.3.1. India Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
13.5.3.1.1. CTLA-4
inhibitors
13.5.3.1.2. LAG-3
inhibitors
13.5.3.1.3. PD-1
inhibitors
13.5.3.1.4. PD-L1
inhibitors
13.5.3.2. India Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
13.5.3.2.1. Bladder
Cancer
13.5.3.2.2. Breast
Cancer
13.5.3.2.3. Lung
Cancer
13.5.3.2.4. Head
and Neck Cancers
13.5.3.2.5. Hodgkin
lymphoma
13.5.3.2.6. Kidney
Cancer
13.5.3.2.7. Melanoma
13.5.3.2.8. Non-small
cell lung cancer
13.5.3.2.9. Stomach
cancer
13.5.3.2.10. Colorectal
cancer
13.5.3.2.11. Others
13.5.3.3. India Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.3.3.1. Hospitals
and clinics
13.5.3.3.2. Specialty
Clinics
13.5.3.3.3. Research
Organizations
13.5.4. New
Zealand
13.5.4.1. New Zealand Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.5.4.1.1. CTLA-4
inhibitors
13.5.4.1.2. LAG-3
inhibitors
13.5.4.1.3. PD-1
inhibitors
13.5.4.1.4. PD-L1
inhibitors
13.5.4.2. New Zealand Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Cancer Type
13.5.4.2.1. Bladder
Cancer
13.5.4.2.2. Breast
Cancer
13.5.4.2.3. Lung
Cancer
13.5.4.2.4. Head
and Neck Cancers
13.5.4.2.5. Hodgkin
lymphoma
13.5.4.2.6. Kidney
Cancer
13.5.4.2.7. Melanoma
13.5.4.2.8. Non-small
cell lung cancer
13.5.4.2.9. Stomach
cancer
13.5.4.2.10. Colorectal
cancer
13.5.4.2.11. Others
13.5.4.3. New Zealand Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By End Users
13.5.4.3.1. Hospitals
and clinics
13.5.4.3.2. Specialty
Clinics
13.5.4.3.3. Research
Organizations
13.5.5. Australia
13.5.5.1. Australia Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
13.5.5.1.1. CTLA-4
inhibitors
13.5.5.1.2. LAG-3
inhibitors
13.5.5.1.3. PD-1
inhibitors
13.5.5.1.4. PD-L1
inhibitors
13.5.5.2. Australia Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
13.5.5.2.1. Bladder
Cancer
13.5.5.2.2. Breast
Cancer
13.5.5.2.3. Lung
Cancer
13.5.5.2.4. Head
and Neck Cancers
13.5.5.2.5. Hodgkin
lymphoma
13.5.5.2.6. Kidney
Cancer
13.5.5.2.7. Melanoma
13.5.5.2.8. Non-small
cell lung cancer
13.5.5.2.9. Stomach
cancer
13.5.5.2.10. Colorectal
cancer
13.5.5.2.11. Others
13.5.5.3. Australia Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
13.5.5.3.1. Hospitals
and clinics
13.5.5.3.2. Specialty
Clinics
13.5.5.3.3. Research
Organizations
13.5.6. South
Korea
13.5.6.1. South Korea Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.5.6.1.1. CTLA-4
inhibitors
13.5.6.1.2. LAG-3
inhibitors
13.5.6.1.3. PD-1
inhibitors
13.5.6.1.4. PD-L1
inhibitors
13.5.6.2. South Korea Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Cancer Type
13.5.6.2.1. Bladder
Cancer
13.5.6.2.2. Breast
Cancer
13.5.6.2.3. Lung
Cancer
13.5.6.2.4. Head
and Neck Cancers
13.5.6.2.5. Hodgkin
lymphoma
13.5.6.2.6. Kidney
Cancer
13.5.6.2.7. Melanoma
13.5.6.2.8. Non-small
cell lung cancer
13.5.6.2.9. Stomach
cancer
13.5.6.2.10. Colorectal
cancer
13.5.6.2.11. Others
13.5.6.3. South Korea Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By End Users
13.5.6.3.1. Hospitals
and clinics
13.5.6.3.2. Specialty
Clinics
13.5.6.3.3. Research
Organizations
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
13.5.7.1.1. CTLA-4
inhibitors
13.5.7.1.2. LAG-3
inhibitors
13.5.7.1.3. PD-1
inhibitors
13.5.7.1.4. PD-L1
inhibitors
13.5.7.2. Southeast Asia Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Cancer Type
13.5.7.2.1. Bladder
Cancer
13.5.7.2.2. Breast
Cancer
13.5.7.2.3. Lung
Cancer
13.5.7.2.4. Head
and Neck Cancers
13.5.7.2.5. Hodgkin
lymphoma
13.5.7.2.6. Kidney
Cancer
13.5.7.2.7. Melanoma
13.5.7.2.8. Non-small
cell lung cancer
13.5.7.2.9. Stomach
cancer
13.5.7.2.10. Colorectal
cancer
13.5.7.2.11. Others
13.5.7.3. Southeast Asia Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By End Users
13.5.7.3.1. Hospitals
and clinics
13.5.7.3.2. Specialty
Clinics
13.5.7.3.3. Research
Organizations
13.5.7.4. Southeast Asia Immune Checkpoint Inhibitors Market Revenue
(US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Drug Class
13.5.8.1.1. CTLA-4
inhibitors
13.5.8.1.2. LAG-3
inhibitors
13.5.8.1.3. PD-1
inhibitors
13.5.8.1.4. PD-L1
inhibitors
13.5.8.2. Rest of Asia Pacific Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
13.5.8.2.1. Bladder
Cancer
13.5.8.2.2. Breast
Cancer
13.5.8.2.3. Lung
Cancer
13.5.8.2.4. Head
and Neck Cancers
13.5.8.2.5. Hodgkin
lymphoma
13.5.8.2.6. Kidney
Cancer
13.5.8.2.7. Melanoma
13.5.8.2.8. Non-small
cell lung cancer
13.5.8.2.9. Stomach
cancer
13.5.8.2.10. Colorectal
cancer
13.5.8.2.11. Others
13.5.8.3. Rest of Asia Pacific Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.8.3.1. Hospitals
and clinics
13.5.8.3.2. Specialty
Clinics
13.5.8.3.3. Research
Organizations
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Drug
Class
13.6.3. By
Cancer Type
13.6.4. By End
Users
14. Middle East and Africa Immune Checkpoint Inhibitors Market
Analysis and Forecasts, 2023 – 2031
14.1. Overview
14.1.1. Middle
East and Africa Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
14.2. Middle
East and Africa Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.2.1. CTLA-4
inhibitors
14.2.2. LAG-3
inhibitors
14.2.3. PD-1
inhibitors
14.2.4. PD-L1
inhibitors
14.3. Middle
East and Africa Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.3.1. Bladder
Cancer
14.3.2. Breast
Cancer
14.3.3. Lung
Cancer
14.3.4. Head
and Neck Cancers
14.3.5. Hodgkin
lymphoma
14.3.6. Kidney
Cancer
14.3.7. Melanoma
14.3.8. Non-small
cell lung cancer
14.3.9. Stomach
cancer
14.3.10. Colorectal
cancer
14.3.11. Others
14.4. Middle
East and Africa Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
14.4.1. Hospitals
and clinics
14.4.2. Specialty
Clinics
14.4.3. Research
Organizations
14.5. Middle
East and Africa Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
14.5.1.1.1. CTLA-4
inhibitors
14.5.1.1.2. LAG-3
inhibitors
14.5.1.1.3. PD-1
inhibitors
14.5.1.1.4. PD-L1
inhibitors
14.5.1.2. Saudi Arabia Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Cancer Type
14.5.1.2.1. Bladder
Cancer
14.5.1.2.2. Breast
Cancer
14.5.1.2.3. Lung
Cancer
14.5.1.2.4. Head
and Neck Cancers
14.5.1.2.5. Hodgkin
lymphoma
14.5.1.2.6. Kidney
Cancer
14.5.1.2.7. Melanoma
14.5.1.2.8. Non-small
cell lung cancer
14.5.1.2.9. Stomach
cancer
14.5.1.2.10. Colorectal
cancer
14.5.1.2.11. Others
14.5.1.3. Saudi Arabia Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By End Users
14.5.1.3.1. Hospitals
and clinics
14.5.1.3.2. Specialty
Clinics
14.5.1.3.3. Research
Organizations
14.5.2. UAE
14.5.2.1. UAE Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.5.2.1.1. CTLA-4
inhibitors
14.5.2.1.2. LAG-3
inhibitors
14.5.2.1.3. PD-1
inhibitors
14.5.2.1.4. PD-L1
inhibitors
14.5.2.2. UAE Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.5.2.2.1. Bladder
Cancer
14.5.2.2.2. Breast
Cancer
14.5.2.2.3. Lung
Cancer
14.5.2.2.4. Head
and Neck Cancers
14.5.2.2.5. Hodgkin
lymphoma
14.5.2.2.6. Kidney
Cancer
14.5.2.2.7. Melanoma
14.5.2.2.8. Non-small
cell lung cancer
14.5.2.2.9. Stomach
cancer
14.5.2.2.10. Colorectal
cancer
14.5.2.2.11. Others
14.5.2.3. UAE Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.2.3.1. Hospitals
and clinics
14.5.2.3.2. Specialty
Clinics
14.5.2.3.3. Research
Organizations
14.5.3. Egypt
14.5.3.1. Egypt Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Drug Class
14.5.3.1.1. CTLA-4
inhibitors
14.5.3.1.2. LAG-3
inhibitors
14.5.3.1.3. PD-1
inhibitors
14.5.3.1.4. PD-L1
inhibitors
14.5.3.2. Egypt Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By Cancer Type
14.5.3.2.1. Bladder
Cancer
14.5.3.2.2. Breast
Cancer
14.5.3.2.3. Lung
Cancer
14.5.3.2.4. Head
and Neck Cancers
14.5.3.2.5. Hodgkin
lymphoma
14.5.3.2.6. Kidney
Cancer
14.5.3.2.7. Melanoma
14.5.3.2.8. Non-small
cell lung cancer
14.5.3.2.9. Stomach
cancer
14.5.3.2.10. Colorectal
cancer
14.5.3.2.11. Others
14.5.3.3. Egypt Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and
Forecasts, By End Users
14.5.3.3.1. Hospitals
and clinics
14.5.3.3.2. Specialty
Clinics
14.5.3.3.3. Research
Organizations
14.5.4. Kuwait
14.5.4.1. Kuwait Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
14.5.4.1.1. CTLA-4
inhibitors
14.5.4.1.2. LAG-3
inhibitors
14.5.4.1.3. PD-1
inhibitors
14.5.4.1.4. PD-L1
inhibitors
14.5.4.2. Kuwait Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
14.5.4.2.1. Bladder
Cancer
14.5.4.2.2. Breast
Cancer
14.5.4.2.3. Lung
Cancer
14.5.4.2.4. Head
and Neck Cancers
14.5.4.2.5. Hodgkin
lymphoma
14.5.4.2.6. Kidney
Cancer
14.5.4.2.7. Melanoma
14.5.4.2.8. Non-small
cell lung cancer
14.5.4.2.9. Stomach
cancer
14.5.4.2.10. Colorectal
cancer
14.5.4.2.11. Others
14.5.4.3. Kuwait Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
14.5.4.3.1. Hospitals
and clinics
14.5.4.3.2. Specialty
Clinics
14.5.4.3.3. Research
Organizations
14.5.5. South
Africa
14.5.5.1. South Africa Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Drug Class
14.5.5.1.1. CTLA-4
inhibitors
14.5.5.1.2. LAG-3
inhibitors
14.5.5.1.3. PD-1
inhibitors
14.5.5.1.4. PD-L1
inhibitors
14.5.5.2. South Africa Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By Cancer Type
14.5.5.2.1. Bladder
Cancer
14.5.5.2.2. Breast
Cancer
14.5.5.2.3. Lung
Cancer
14.5.5.2.4. Head
and Neck Cancers
14.5.5.2.5. Hodgkin
lymphoma
14.5.5.2.6. Kidney
Cancer
14.5.5.2.7. Melanoma
14.5.5.2.8. Non-small
cell lung cancer
14.5.5.2.9. Stomach
cancer
14.5.5.2.10. Colorectal
cancer
14.5.5.2.11. Others
14.5.5.3. South Africa Immune Checkpoint Inhibitors Market Revenue (US$
Mn) and Forecasts, By End Users
14.5.5.3.1. Hospitals
and clinics
14.5.5.3.2. Specialty
Clinics
14.5.5.3.3. Research
Organizations
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Immune Checkpoint Inhibitors
Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.5.6.1.1. CTLA-4
inhibitors
14.5.6.1.2. LAG-3
inhibitors
14.5.6.1.3. PD-1
inhibitors
14.5.6.1.4. PD-L1
inhibitors
14.5.6.2. Rest of Middle East & Africa Immune Checkpoint Inhibitors
Market Revenue (US$ Mn) and Forecasts, By Cancer Type
14.5.6.2.1. Bladder
Cancer
14.5.6.2.2. Breast
Cancer
14.5.6.2.3. Lung
Cancer
14.5.6.2.4. Head
and Neck Cancers
14.5.6.2.5. Hodgkin
lymphoma
14.5.6.2.6. Kidney
Cancer
14.5.6.2.7. Melanoma
14.5.6.2.8. Non-small
cell lung cancer
14.5.6.2.9. Stomach
cancer
14.5.6.2.10. Colorectal
cancer
14.5.6.2.11. Others
14.5.6.3. Rest of Middle East & Africa Immune Checkpoint Inhibitors
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals
and clinics
14.5.6.3.2. Specialty
Clinics
14.5.6.3.3. Research
Organizations
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Drug
Class
14.6.3. By
Cancer Type
14.6.4. By End
Users
15. Latin America Immune Checkpoint Inhibitors Market Analysis
and Forecasts, 2023 – 2031
15.1. Overview
15.1.1. Latin
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
15.2. Latin
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Drug Class
15.2.1. CTLA-4
inhibitors
15.2.2. LAG-3
inhibitors
15.2.3. PD-1
inhibitors
15.2.4. PD-L1
inhibitors
15.3. Latin
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
Cancer Type
15.3.1. Bladder
Cancer
15.3.2. Breast
Cancer
15.3.3. Lung
Cancer
15.3.4. Head
and Neck Cancers
15.3.5. Hodgkin
lymphoma
15.3.6. Kidney Cancer
15.3.7. Melanoma
15.3.8. Non-small
cell lung cancer
15.3.9. Stomach
cancer
15.3.10. Colorectal
cancer
15.3.11. Others
15.4. Latin
America Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By
End Users
15.4.1. Hospitals
and clinics
15.4.2. Specialty
Clinics
15.4.3. Research
Organizations
15.5. Latin America
Immune Checkpoint Inhibitors Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
15.5.1.1.1. CTLA-4
inhibitors
15.5.1.1.2. LAG-3
inhibitors
15.5.1.1.3. PD-1
inhibitors
15.5.1.1.4. PD-L1
inhibitors
15.5.1.2. Brazil Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
15.5.1.2.1. Bladder
Cancer
15.5.1.2.2. Breast
Cancer
15.5.1.2.3. Lung
Cancer
15.5.1.2.4. Head
and Neck Cancers
15.5.1.2.5. Hodgkin
lymphoma
15.5.1.2.6. Kidney
Cancer
15.5.1.2.7. Melanoma
15.5.1.2.8. Non-small
cell lung cancer
15.5.1.2.9. Stomach
cancer
15.5.1.2.10. Colorectal
cancer
15.5.1.2.11. Others
15.5.1.3. Brazil Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
15.5.1.3.1. Hospitals
and clinics
15.5.1.3.2. Specialty
Clinics
15.5.1.3.3. Research
Organizations
15.5.2. Argentina
15.5.2.1. Argentina Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Drug Class
15.5.2.1.1. CTLA-4
inhibitors
15.5.2.1.2. LAG-3
inhibitors
15.5.2.1.3. PD-1
inhibitors
15.5.2.1.4. PD-L1
inhibitors
15.5.2.2. Argentina Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By Cancer Type
15.5.2.2.1. Bladder
Cancer
15.5.2.2.2. Breast
Cancer
15.5.2.2.3. Lung
Cancer
15.5.2.2.4. Head
and Neck Cancers
15.5.2.2.5. Hodgkin
lymphoma
15.5.2.2.6. Kidney
Cancer
15.5.2.2.7. Melanoma
15.5.2.2.8. Non-small
cell lung cancer
15.5.2.2.9. Stomach
cancer
15.5.2.2.10. Colorectal
cancer
15.5.2.2.11. Others
15.5.2.3. Argentina Immune Checkpoint Inhibitors Market Revenue (US$ Mn)
and Forecasts, By End Users
15.5.2.3.1. Hospitals
and clinics
15.5.2.3.2. Specialty
Clinics
15.5.2.3.3. Research
Organizations
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Drug Class
15.5.3.1.1. CTLA-4
inhibitors
15.5.3.1.2. LAG-3
inhibitors
15.5.3.1.3. PD-1
inhibitors
15.5.3.1.4. PD-L1
inhibitors
15.5.3.2. Rest of Latin America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By Cancer Type
15.5.3.2.1. Bladder
Cancer
15.5.3.2.2. Breast
Cancer
15.5.3.2.3. Lung
Cancer
15.5.3.2.4. Head
and Neck Cancers
15.5.3.2.5. Hodgkin
lymphoma
15.5.3.2.6. Kidney
Cancer
15.5.3.2.7. Melanoma
15.5.3.2.8. Non-small
cell lung cancer
15.5.3.2.9. Stomach
cancer
15.5.3.2.10. Colorectal
cancer
15.5.3.2.11. Others
15.5.3.3. Rest of Latin America Immune Checkpoint Inhibitors Market
Revenue (US$ Mn) and Forecasts, By End Users
15.5.3.3.1. Hospitals
and clinics
15.5.3.3.2. Specialty
Clinics
15.5.3.3.3. Research
Organizations
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Drug
Class
15.6.3. By
Cancer Type
15.6.4. By End
Users
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market
Share Analysis, 2022
16.3. Global
Presence and Growth Strategies
16.3.1. Mergers
and Acquisitions
16.3.2. Product
Launches
16.3.3. Investments
Trends
16.3.4. R&D
Initiatives
17. Player Profiles
17.1. AstraZeneca
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. BeiGene, Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Bristol Myers Squibb
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. DeuterOncology
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Eli Lilly and Company
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. F. Hoffman-La Roche Ltd
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. GSK plc
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Merck & Co. Inc
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT Analysis
17.8.7. Business
Strategies
17.9. Novartis AG
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Palleon Pharmaceuticals
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Sanofi
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Other
Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.